IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) in May 2025. IDL Diagnostics AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Hultman, Anders

Employees

Website

www.arocell.com

IPO Date

2025-05-19

Headquarters

KarlsbodavAegen 39, Bromma, Stockholm, Stockholm County, 168 67, Sweden

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

IDL Diagnostics IDLDX

IDL Diagnostics Earnings Call Summary

IDL Diagnostics Earnings

Transcripts

Events

About IDL Diagnostics AB (publ)

IDL Diagnostics
IDLDX